Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Aims to Raise $10.7M

NEW YORK (GenomeWeb) – Vermillion said today that it is issuing a private placement that could raise around $10.7 million.

The placement consists of about 3.7 million shares of Vermillion common stock to be sold at $1.40 per share — the stock's closing price on Feb. 10 — as well as warrants to purchase up to 2.8 million shares of common stock for $1.80 per share.

The warrants can be exercised six months after the placement closes and will expire five years after the date they are issued, or five days after Vermillion notifies investors that the closing price per share had exceeded the exercise price for 20 consecutive trading days.

According to the company, several Vermillion directors, members of management, and significant stockholders have agreed to purchase the shares.

The placement, which is expected to occur on Feb. 17, will raise $5.6 million before transaction costs from the offering of common stock, and another $5.1 million before transaction costs if all the warrants are exercised.

The company said it will use the proceeds for general corporate and working capital purposes.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.